Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1/2A Study of Rintatolimod and IFN-Alpha Regimen in Cancer Patients With Mild or Moderate COVID-19 Infection

Trial Profile

Phase 1/2A Study of Rintatolimod and IFN-Alpha Regimen in Cancer Patients With Mild or Moderate COVID-19 Infection

Status: Not yet recruiting
Phase of Trial: Phase I/II

Latest Information Update: 13 Jul 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Interferon alpha-2b (Primary) ; Rintatolimod (Primary)
  • Indications Adult respiratory distress syndrome; COVID 2019 infections
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Most Recent Events

    • 09 Jul 2020 According to a AIM ImmunoTech media release, the company will provide Ampligen (rintatolimod) at no charge for this study.
    • 09 Jul 2020 According to a AIM ImmunoTech media release, enrollment of the patients will be conducted at Roswell Park under the clinical leadership of Brahm Segal, MD, Chair of Internal Medicine and Chief of Infectious Diseases at the Buffalo, N.Y.-based cancer center and is expected to begin within 30 days.
    • 09 Jul 2020 According to a AIM ImmunoTech media release, the trial is funded partly through grants from the National Cancer Institute and AIM, as well as institutional support from Roswell Park.
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top